Educational information, not medical advice — ask your doctor or midwife.
Glucagon is a peptide hormone naturally produced by the alpha cells of the pancreas. It acts as the body's built-in blood sugar rescue signal — when glucose drops too low, glucagon tells the liver to release stored sugar back into the bloodstream. GlucaGen is a pharmaceutical-grade recombinant version of this hormone, chemically identical to what your body makes, used when the body's own emergency system isn't enough.
Glucagon binds to receptors on liver cells and triggers the breakdown of stored glycogen into glucose, rapidly releasing it into the blood. It also stimulates the liver to produce new glucose from non-sugar sources. This dual action makes it highly effective at reversing dangerous blood sugar crashes within minutes — even in someone who is unconscious and cannot take food or drink by mouth.
The original GlucaGen kit requires mixing a powder with liquid before injection — effective but requires some preparation. Newer formulations make emergency use much simpler: Baqsimi is a nasal powder that requires no needles; Gvoke is an autoinjector pen; Zegalogue (dasiglucagon) is a next-generation prefilled syringe. All forms are prescription-only and intended for emergency use or clinical settings.
Glucagon was first isolated from pancreatic tissue in 1923, shortly after insulin's discovery. Its clinical use as an emergency hypoglycemia rescue agent became standard of care through the latter half of the 20th century. Recombinant DNA production (GlucaGen) replaced animal-derived glucagon in the 1990s, improving purity and consistency. Needle-free delivery systems (Baqsimi nasal powder) received FDA approval in 2019, dramatically lowering the barrier to emergency use by untrained bystanders.
Evidence grades and traditional-use labels are explained in our methodology. Nothing here is medical advice.
Reviewed by the HealisticMD editorial team How we grade evidence →
What it is typically used for, usual dose, cautions, and the study behind it where real trial data exists.
One email with the summary. We'll also send a short weekly evidence update — unsubscribe any time.